Neurorestoration therapeutics for neurodegenerative and psychiatric disease

Neurological Research

Volumn 34, Issue 2, 2012, Pages 129-142

  Bednar, Martin M ^a   Perry, Ann ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Gene therapy; Neurorestoration; Stem cells; Trophic factors

Indexed keywords

ALEMTUZUMAB; ANTIPARKINSON AGENT; ATORVASTATIN; BETA INTERFERON; BETA1A INTERFERON; CENPLACEL L; CERE 120; ERYTHROPOIETIN; GLYCOSIDE; LEUPRORELIN; LITHIUM CARBONATE; METHYLPREDNISOLONE SULEPTANATE; NERVE GROWTH FACTOR; NGN 9076; OCRELIZUMAB; PROSAVIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; TESAMORELIN; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAINSTORMING; CELL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CISTANCHE; DEGENERATIVE DISEASE; DEPRESSION; EPILEPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MENTAL DISEASE; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEURORESTORATION; PARKINSON DISEASE; REVIEW; SPINAL CORD INJURY; SPINAL MUSCULAR ATROPHY; STEM CELL; STROKE; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; NERVE REGENERATION; NEURODEGENERATIVE DISEASES; NEUROGENESIS; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

EID: 84857938235     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000069     Document Type: Review

References (54)

1. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-7.
2. Cajal SRY. Degeneration and regeneration of the nervous system. In: DeFelipe J, Jones EG, editors. Cajal's degeneration and regeneration of the nervous system. New York: Oxford University Press; 1991. pp. 747-50.
3. Farin A, Liu CY, Elder JB, Langmoen IA, Apuzzo ML. The biological restoration of central nervous system architecture and function: Part 1-foundations and historical landmarks in contemporary stem cell biology. Neurosurgery 2009;64:15-39.
4. Farin A, Liu CY, Langmoen IA, Apuzzo ML. The biological restoration of central nervous system architecture and function: Part 2 - emergence of the realization of adult neurogenesis. Neurosurgery 2009;64:581-60.
5. Farin A, Liu CY, Langmoen IA, Apuzzo ML. Biological restoration of central nervous system architecture and function: Part 3 - stem cell- and cell-based applications and realities in the biological management of central nervous system disorders: traumatic, vascular, and epilepsy disorders. Neurosurgery 2009;65:831-59.
6. Kelsch W, Sim S, Lois C. Watching synaptogenesis in the adult brain. Annu Rev Neurosci 2010;33:131-49.
7. Koch P, Kokaia Z, Lindvall O, Brüstle O. Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. Lancet Neurol 2009;8:819-29.
8. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009;87:2183-200.
9. Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C. The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One 2010;5:e11231.
10. Kleim JA, Jones TA, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury. Neurochem Res 2003;28:1757-69.
11. Navaratna D, Guo S, Arai K, Lo EH. Mechanisms and targets for angiogenic therapy after stroke. Cell Adh Migr 2009;3:216-23.
12. Raivich G, Makwana M. The making of successful axonal regeneration: genes, molecules and signal transduction pathways Brain Res Rev 2007;53:287-311.
13. Thompson HJ, Marklund N, LeBold DG, Morales DM, Keck CA, Vinson M, et al. Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody. Eur J Neurosci 2006;24:3063-72.
14. Bednar MM. The role of sildenafil in the treatment of stroke. Curr Opin Invest Drugs 2008;9:754-59.
15. Skaper SD. Signalling pathways with small molecule mimetics and modulators to achieve neuroprotection and regeneration. CNS Neurol Disord Drug Targets 2008;7:45.
16. Donnan GA. The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke 2008;39:242.
17. Schoepp DD. Where will new neuroscience therapies come from? Nat Rev 2011;10:715-6.
18. Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
19. Caplan CR, Arenillas J, Cramer SC, Joutel A, Lo EH, Meschia J, et al. Stroke-related translational research. Arch Neurol 2011;68:1110-23.
20. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood- brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009;118:103-13.
21. Chen J, Zhang, ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-51.
22. Nudo RJ. Plasticity. NeuroRx 2006;3:420-7.
23. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002;33:2675-80.
24. Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, et al. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res 2006;1118:192-8.
25. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123-30.
26. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother 2008;8:1193-201.
27. Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke 2011;42:825-9.
28. Allan LE, Petit GH, Brundin P. Cell transplantation in Parkinson's disease: problems and perspectives. Curr Opin Neurol 2010;23:426-32.
29. Lévesque MF, Neuman T, Rezak M. Therapeutic microinjection of autologous adult human neural stem cells and differentiated neurons for Parkinson's disease: five-year postoperative outcome. Open Stem Cell J 2009;1:20-9.
30. Xu L, Ryugo DK, Pongstaporn T, Johe K, Koliatsos VE. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration intothe segmental motor circuitry. J Comp Neurol 2009;514:297-309.
31. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413-7.
32. Bogaert E, van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, et al. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging 2010;31:2185-91.
33. Jung KH, Chua K, Lee ST. Granulocyte colony-stimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAT activation. Brain Res 2006;1073-1074:190-201.
34. Auld DS, Mennicken F, Quirion R. Nerve growth factor rapidly induces prolonged acetylcholine release from cultured basal forebrain neurons: differentiation between neuromodulatory and neurotrophic influences. J Neurosci 2001;21:3375-82.
35. Enciu AM, Nicolescu MI, Manole CG, Mureşanu DF, Popescu LM, Popescu BO. Neuroregeneration in neurodegenerative disorders. BMC Neurol 2011;11:75.
36. Dupuis L, Gonzalez de Aguilar J, di Scala F, Rene F, de Tapia M, Pradat PF, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:358.
37. Available from: http://www.clinicaltrials.gov/ct2/show/NCT007 53571?term5cistanche&rank51.
38. Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs 2008;22:265-73.
39. Walmsley AR, Mir AK. Targeting the Nogo-A signalling pathway to promote recovery following acute CNS injury. Curr Pharm Des 2007;13:2470-84.
40. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-94.
41. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood- brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
42. Byts N, Siren AL. Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med 2009;1:1-4.
43. Baker L, Borson S, Merriam G, Friedman SD, CraftBars S, Vitiello MV. Tesamorelin, a growth hormone releasing hormone analogue, improves cognitive function in MCI and healthy aging: results of a randomized controlled trial. Alzheimer's Dement 2011;7:S514.
44. Bondanelli M, Ambrosio MR, Zatelli MC, Basaglia N, Degli-Uberti EC. Hypopituitarism after traumatic brain injury. Eur J Endocrinol 2005;152:679-91.
45. Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, et al. GM-CSF up-regulated in Rheumatoid Arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimer's Dis 21:507-518.
46. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Exp Opin Invest Drugs 2007;16:1851-63.
47. Witt J, Marks WJ. An update on gene therapy in Parkinson's disease. Curr Neurol Neurosci Rep 2011;11:362-70.
48. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, et al. Bioactivity of AAV2-Neurturin Gene Therapy (CERE- 120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2010;26:27-36.
49. von Bohlen, Halbach O, Unsicker K. Neurotrophic support of midbrain dopaminergic neurons. Adv Exp Med Biol 2009;651:73-80.
50. Tsai LK, Wang Z, Munasinghe J, Leng Y, Leeds P, Chuang DM, et al. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 2011;42:2932-9.
51. Trebst C, Voss E, Skripuletz T, Stangel M. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. Curr Med Chem 2010;17:640-50.
52. Bartels C, Spate K, Krampe H, Ehrenreich H. Review: recombinant human erythropoietin: novel strategies for neuroprotective/ neuroregenerative treatment of multiple sclerosis. Therap Adv Neurol Disord 2008;1:193-206.
53. Nirula R, Diaz-Arrastia R, Brasel K, Weigelt JA, Waxman K. Case report: safety and efficacy of erythropoietin in traumatic brain injury patients: a pilot randomized trial. Crit Care Res Pract 2010;2010:Article ID 209848
54. Carelli S, Marfia G, Di Giulio AM, Ghilardi G, Gorio A. Erythropoietin: recent developments in the treatment of spinal cord injury. Neurol Res Int 2011;2011:Article ID 453179.